1. Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020;8:726–737.

2. Araki T, Putman RK, Hatabu H, et al. Development and Progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med 2016;194:1514–1522.

3. Lee TS, Jin KN, Lee HW, et al. Interstitial lung abnormalities and the clinical course in patients with COPD. Chest 2021;159:128–137.

4. Mackintosh JA, Marshall HM, Slaughter R, et al. Interstitial lung abnormalities in the Queensland Lung Cancer Screening Study: prevalence and progression over 2 years of surveillance. Intern Med J 2019;49:843–849.

5. Hoyer N, Wille MMW, Thomsen LH, et al. Interstitial lung abnormalities are associated with increased mortality in smokers. Respir Med 2018;136:77–82.

6. Lee JE, Chae KJ, Suh YJ, et al. Prevalence and long-term outcomes of CT interstitial lung abnormalities in a health screening cohort. Radiology 2023;306:e221172.

7. Putman RK, Gudmundsson G, Axelsson GT, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med 2019;200:175–183.

8. Hunninghake GM. Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax 2019;74:506–511.

9. Salisbury ML, Hewlett JC, Ding G, et al. Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease. Am J Respir Crit Care Med 2020;201:1230–1239.

10. Doyle TJ, Washko GR, Fernandez IE, et al. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med 2012;185:756–762.

11. Zhang Y, Wan H, Richeldi L, et al. Reticulation is a risk factor of progressive subpleural nonfibrotic interstitial lung abnormalities. Am J Respir Crit Care Med 2022;206:178–185.

12. Oldham JM, Adegunsoye A, Khera S, et al. Underreporting of interstitial lung abnormalities on lung cancer screening computed tomography. Ann Am Thorac Soc 2018;15:764–766.

13. Jin GY, Lynch D, Chawla A, et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 2013;268:563–571.

14. Hida T, Nishino M, Hino T, et al. Traction bronchiectasis/bronchiolectasis is associated with interstitial lung abnormality mortality. Eur J Radiol 2020;129:109073.

15. Hata A, Schiebler ML, Lynch DA, Hatabu H. Interstitial lung abnormalities: state of the art. Radiology 2021;301:19–34.

16. Kashiwabara K, Kohshi S. Additional computed tomography scans in the prone position to distinguish early interstitial lung disease from dependent density on helical computed tomography screening patient characteristics. Respirology 2006;11:482–487.

17. Arakawa H, Niimi H, Kurihara Y, Nakajima Y, Webb WR. Expiratory high-resolution CT: diagnostic value in diffuse lung diseases. AJR Am J Roentgenol 2000;175:1537–1543.

18. McGroder CF, Hansen S, Hinckley Stukovsky K, et al. Incidence of interstitial lung abnormalities: the MESA Lung Study. Eur Respir J 2023;61:2201950.

19. Kim MS, Choe J, Hwang HJ, et al. Interstitial lung abnormalities (ILA) on routine chest CT: comparison of radiologists’ visual evaluation and automated quantification. Eur J Radiol 2022;157:110564.

20. Chae KJ, Lim S, Seo JB, et al. Interstitial lung abnormalities at CT in the Korean National Lung Cancer Screening Program: prevalence and deep learning-based texture analysis. Radiology 2023;307:e222828.

21. Easthausen I, Podolanczuk A, Hoffman E, et al. Reference values for high attenuation areas on chest CT in a healthy, never-smoker, multi-ethnic sample: The MESA study. Respirology 2020;25:855–862.

22. Oh JH, Kim GHJ, Song JW. Interstitial lung abnormality evaluated by an automated quantification system: prevalence and progression rate. Respir Res 2024;25:78.

23. Kliment CR, Araki T, Doyle TJ, et al. A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulm Med 2015;15:134.

24. Podolanczuk AJ, Oelsner EC, Barr RG, et al. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J 2016;48:1442–1452.

25. Podolanczuk AJ, Raghu G, Tsai MY, et al. Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study. Thorax 2017;72:472–474.

26. Mathai SK, Humphries S, Kropski JA, et al. MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. Thorax 2019;74:1131–1139.

27. Putman RK, Hatabu H, Araki T, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA 2016;315:672–681.

28. Rose JA, Menon AA, Hino T, et al. Suspected interstitial lung disease in COPDGene study. Am J Respir Crit Care Med 2023;207:60–68.

29. Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med 2010;104:1712–1721.

30. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013;368:2192–2200.

31. Peljto AL, Selman M, Kim DS, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest 2015;147:460–464.

32. Sanders JL, Putman RK, Dupuis J, et al. The association of aging biomarkers, interstitial lung abnormalities, and mortality. Am J Respir Crit Care Med 2021;203:1149–1157.

33. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897–906.

34. Pesonen I, Johansson F, Johnsson Å, et al. High prevalence of interstitial lung abnormalities in middle-aged never-smokers. ERJ Open Res 2023;9:00035–2023.

35. Sack CS, Doney BC, Podolanczuk AJ, et al. Occupational exposures and subclinical interstitial lung disease. The MESA (Multi-Ethnic Study of Atherosclerosis) air and lung studies. Am J Respir Crit Care Med 2017;196:1031–1039.

36. Johannson KA, Balmes JR, Collard HR. Air pollution exposure: a novel environmental risk factor for interstitial lung disease? Chest 2015;147:1161–1167.

37. Sack C, Vedal S, Sheppard L, et al. Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study. Eur Respir J 2017;50:1700559.

38. Rice MB, Li W, Schwartz J, et al. Ambient air pollution exposure and risk and progression of interstitial lung abnormalities: the Framingham Heart Study. Thorax 2019;74:1063–1069.

39. Zhang Q, Wang Y, Qu D, Yu J, Yang J. The possible pathogenesis of idiopathic pulmonary fibrosis considering MUC5B . Biomed Res Int 2019;2019:9712464.

40. Hobbs BD, Putman RK, Araki T, et al. Overlap of genetic risk between interstitial lung abnormalities and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019;200:1402–1413.

41. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083–2092.

42. Axelsson GT, Gudmundsson G, Pratte KA, et al. The proteomic profile of interstitial lung abnormalities. Am J Respir Crit Care Med 2022;206:337–346.

43. Tomassetti S, Poletti V, Ravaglia C, et al. Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. Eur Respir Rev 2022;31:210206.

44. Ichikado K, Ichiyasu H, Iyonaga K, et al. An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J). BMC Pulm Med 2023;23:199.

45. Sanders JL, Axelsson G, Putman R, et al. The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study. Thorax 2023;78:559–565.

46. Seok J, Park S, Yoon EC, Yoon HY. Clinical outcomes of inter- stitial lung abnormalities: a systematic review and meta-analysis. Sci Rep 2024;14:7330.

47. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer 2013;82:260–265.

48. Li F, Zhou Z, Wu A, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol 2018;13:82.

49. Nakanishi Y, Masuda T, Yamaguchi K, et al. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig 2019;57:451–459.

50. Im Y, Park HY, Shin S, et al. Prevalence of and risk factors for pulmonary complications after curative resection in otherwise healthy elderly patients with early stage lung cancer. Respir Res 2019;20:136.

51. Park S, Choe J, Hwang HJ, et al. Long-term follow-up of interstitial lung abnormality: implication in follow-up strategy and risk thresholds. Am J Respir Crit Care Med 2023;208:858–867.